论文部分内容阅读
为探讨必可酮(BDP)防治儿童哮喘的价值,我们以吸入BDP为主防治儿童哮喘118例,均随访2午以上,年龄5～14岁,平均病程5.1年.轻、中、重症分别为15.46和57例.BDP每日吸入300～400μg,连用1年以上,发作时辅以对症治疗,重症给全身激素3～5天。结果:近期总有效率96.61％,远期疗效为94.54％。治疗3个月后PEFR明显升高,停药1年后仍在正常范围.嗜酸粒细胞自治后5个月起明显降低,血清皮质醇(F)治前显著降低,治后1年略升高,停药1年后明显升高。表明该法治疗哮喘效果满意且稳定,对肾上腺皮质功能无明显影响。
In order to explore the value of BDP in the prevention and treatment of childhood asthma, 118 cases of children with BDP-based prevention and treatment of childhood asthma were followed up for more than 2 years, ranging in age from 5 to 14 years with an average duration of 5.1 years, with mild, moderate and severe cases respectively 15.46 and 57. BDP daily inhalation 300 ~ 400μg, used in conjunction for more than 1 year, seizures supplemented by symptomatic treatment, severe to systemic hormones 3 to 5 days. Results: The total effective rate 96.61%, long-term efficacy 94.54%. After 3 months of treatment, the PEFR was significantly increased and remained within the normal range after 1 year of withdrawal.After 5 months, the eosinophil autopsy decreased significantly, serum cortisol (F) High, withdrawal significantly increased after 1 year. The results show that the treatment of asthma with satisfactory results and stability, no significant effect on the adrenal cortex.